• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT beats Q3 sales estimates, raises full-year forecast

November 3, 2017 By Sarah Faulkner

Intersect ENTShares in Intersect ENT (NSDQ:XENT) rose slightly today after the steroid-eluting implant maker beat sales expectations on Wall Street with its third quarter results.

The Menlo Park, Calif.-based company posted a net loss of -$4.3 million on sales of $22.3 million for the 3 months ended Sept. 30, for sales growth of 21% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -15¢, five cents ahead of consensus on The Street, where analysts were looking for sales of $21.5 million.

Intersect ENT raised its full-year sales guidance from $91 – $93 million to $94.1 – $94.6 million.

The company’s steroid-releasing implant, Sinuva, is on track for commercialization in the second quarter of 2018, management reported. The FDA is slated to decide whether to approve the therapy or not by Jan. 7.

The Sinuva implant, which was previously called the Resolve implant, is placed during an in-office doctors appointment and is designed to be a treatment option for patients with recurrent ethmoid sinus obstruction. Traditionally, treatment for the condition includes high-dose oral steroids and repeat surgery.

The company also said in its earnings call that it plans to launch a new clinical study of Sinuva in the fourth quarter this year to evaluate the repeated use of the implant. The 50-patient trial will focus on assessing repeat placement of Sinuva in chronic sinusitis patients with nasal polyps.

The FDA has confirmed that the results of this new study are not required for Sinuva’s approval, according to Leerink analysts Danielle Antalffy and Rebecca Wang.

XENT shares were trading at $28.25 apiece today in early-morning trading, down -1.7%.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS